Biliary Cancer Clinical Trials

2 recruiting

Biliary Cancer Trials at a Glance

12 actively recruiting trials for biliary cancer are listed on ClinicalTrialsFinder across 6 cities in 24 countries. The largest study group is Not Applicable with 4 trials, with the heaviest enrollment activity in Zurich, Bologna, and Athens. Lead sponsors running biliary cancer studies include IRCCS Azienda Ospedaliero-Universitaria di Bologna, Australasian Gastro-Intestinal Cancer Trials Group (AGITG), and AstraZeneca.

Browse biliary cancer trials by phase

Treatments under study

About Biliary Cancer Clinical Trials

Looking for clinical trials for Biliary Cancer? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Biliary Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Biliary Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting

Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)

Breast CancerLung CancerMelanoma+7 more
University Health Network, Toronto7,000 enrolled1 locationNCT07524114
Recruiting
Phase 1Phase 2

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

Biliary CancerBile Duct CancerCancer of the Bile Duct
National Cancer Institute (NCI)60 enrolled1 locationNCT05849480
Recruiting
Not Applicable

Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers

Pancreatic CancerCholangiocarcinomaHepatocellular Carcinoma+3 more
University of California, Irvine15 enrolled1 locationNCT05497531
Recruiting

Observational Study Protocol: LIVER-R

Hepatobiliary Cancers
AstraZeneca4,490 enrolled138 locationsNCT06252753
Recruiting

Effect and Mechanism of ALPPS Operation on Liver Regeneration

Liver CancerHepatobiliary CancersLiver Regeneration+1 more
Haitao Zhao, MD50 enrolled1 locationNCT07142213
Recruiting
Not Applicable

Targeted Navigation in Hepatocellular Carcinoma (HCC)

CholangiocarcinomaHepatocellular CarcinomaHepatobiliary Cancer
University of Miami100 enrolled1 locationNCT06260943
Recruiting
Not Applicable

High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins

Breast CarcinomaHead and Neck CancerThyroid Cancer+10 more
Algemeen Ziekenhuis Maria Middelares150 enrolled1 locationNCT06835426
Recruiting
Phase 1Phase 2

Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors

Breast CancerPancreatic CancerCancer+7 more
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.188 enrolled1 locationNCT06819215
Recruiting

Genotype-phenotype Relationship Between Cryptogenic Cholestasis and Familial Intrahepatic Cholestasis

Hepatobiliary CancerCholestatic Liver DiseaseIntrahepatic Cholestasis+1 more
IRCCS Azienda Ospedaliero-Universitaria di Bologna300 enrolled2 locationsNCT06781242
Recruiting

Familial Intrahepatic Cholestasis-related Genes Associated with Disease Susceptibility in Hepato-biliary Cancers

Hepatobiliary CancersProgressive Familial Intrahepatic Cholestasis (PFIC)Cholestatic Liver Disease
IRCCS Azienda Ospedaliero-Universitaria di Bologna600 enrolled5 locationsNCT06777914
Recruiting
Not Applicable

Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)

Esophageal CancerPancreatic CancerGastric Cancer+12 more
European Organisation for Research and Treatment of Cancer - EORTC200 enrolled13 locationsNCT04498767
Recruiting

Australian Comprehensive Molecular Evaluation of Advanced Biliary Cancer Trial (ACME ABC)

Biliary cancer / Cholangiocarcinoma
Australasian Gastro-Intestinal Cancer Trials Group (AGITG)50 enrolled3 locationsACTRN12622001047785